Chronic wounds are long-term nonhealing wounds that are refractory to treatment. These wounds can present elevated protease levels, leading to rapid degradation of native and exogenously added growth factors. This work focused on developing a protease-resistant growth factor formulation for treatment of chronic wounds presented with high protease activity.
Approach:
This study developed protease-resistant growth factor formulations comprising elastin-like peptides (ELPs) fused with a known protease inhibitor peptide or growth factor. The ELP component of the fusion proteins allows assembly of heterogeneous nanoparticles (NPs) putting the inhibitor in close proximity to the growth factor to be protected.
Results:
We show successful preservation of growth factor activity in high human neutrophil elastase (HNE) environment and in human chronic wound fluid derived from patients. We further show that these NPs result in enhanced collagen remodeling and resolution of inflammation in a full thickness wound supplemented with HNE in genetically diabetic mice.
Innovation:
Development of heterogeneous NPs that put the protease inhibitor in close proximity of the growth factor. Moreover, the modular nature of the NPs allows for protection of multiple growth factors by the same inhibitor without changing the amino acid sequence of the growth factor.
Conclusion:
Our results indicate that the developed NPs hold tremendous promise in chronic wound healing therapy and may further help the translation of growth factor therapies to clinic. The customizable template for the NP design allows for multifaceted use across several fields in research and medicine.
Get full access to this article
View all access options for this article.
References
1.
BerlowitzD, VanDeusen LukasC, ParkerV, et al. Preventing pressure ulcers in hospitals, 2014. www.ahrq.gov/professionals/systems/hospital/pressureulcertoolkit/index.html (last accessed May15, 2019).
2.
ArmstrongDG, BoultonAJM, BusSA. Diabetic foot ulcers and their recurrence. N Engl J Med, 2017; 376:2367–2375.
RysselH, GazyakanE, GermannG, OhlbauerM. The use of MatriDerm in early excision and simultaneous autologous skin grafting in burns—a pilot study. Burns, 2008; 34:93–97.
5.
VelanderP, TheopoldC, BleizifferO, et al.Cell suspensions of autologous keratinocytes or autologous fibroblasts accelerate the healing of full thickness skin wounds in a diabetic porcine wound healing model. J Surg Res, 2009; 157:14–20.
6.
BarberC, WattA, PhamC, et al.Influence of bioengineered skin substitutes on diabetic foot ulcer and venous leg ulcer outcomes. J Wound Care, 2008; 17:517–527.
7.
Grazul-BilskaAT, JohnsonML, BilskiJJ, et al.Wound healing: the role of growth factors. Drugs Today (Barc), 2003; 39:787–800.
8.
HardwickeJ, SchmaljohannD, BoyceD, ThomasD. Epidermal growth factor therapy and wound healing—past, present and future perspectives. Surgeon, 2008; 6:172–177.
9.
HeldinCH, WestermarkB, WastesonA. Specific receptors for platelet-derived growth factor on cells derived from connective tissue and glia. Proc Natl Acad Sci U S A, 1981; 78:3664–3668.
10.
EmbilJM, PappK, SibbaldG, et al.Recombinant human platelet-derived growth factor-BB (becaplermin) for healing chronic lower extremity diabetic ulcers: an open-label clinical evaluation of efficacy. Wound Repair Regen, 2000; 8:162–168.
11.
MaC, HernandezMA, KirkpatrickVE, LiangLJ, NouvongAL, GordonII. Topical platelet-derived growth factor vs placebo therapy of diabetic foot ulcers offloaded with windowed casts: a randomized, controlled trial. Wounds, 2015; 27:83–91.
12.
ReesRS, RobsonMC, SmiellJM, PerryBH. Becaplermin gel in the treatment of pressure ulcers: a phase II randomized, double-blind, placebo-controlled study. Wound Repair Regen, 1999; 7:141–147.
13.
TrengoveNJ, StaceyMC, MacAuleyS, et al.Analysis of the acute and chronic wound environments: the role of proteases and their inhibitors. Wound Repair Regen, 1999; 7:442–452.
14.
YagerDR, NwomehBC. The proteolytic environment of chronic wounds. Wound Repair Regen, 1999; 7:433–441.
15.
WestbyMJ, DumvilleJC, StubbsN, et al.Protease activity as a prognostic factor for wound healing in venous leg ulcers. Cochrane Database Syst Rev, 2018; 9:CD012841.
16.
LobmannR, AmbroschA, SchultzG, WaldmannK, SchiweckS, LehnertH. Expression of matrix-metalloproteinases and their inhibitors in the wounds of diabetic and non-diabetic patients. Diabetologia, 2002; 45:1011–1016.
17.
YagerDR, ZhangLY, LiangHX, DiegelmannRF, CohenIK. Wound fluids from human pressure ulcers contain elevated matrix metalloproteinase levels and activity compared to surgical wound fluids. J Invest Dermatol, 1996; 107:743–748.
18.
MoorAN, VachonDJ, GouldLJ. Proteolytic activity in wound fluids and tissues derived from chronic venous leg ulcers. Wound Repair Regen, 2009; 17:832–839.
19.
McCartySM, PercivalSL. Proteases and delayed wound healing. Adv Wound Care (New Rochelle), 2013; 2:438–447.
20.
SerenaTE, CullenBM, BayliffSW, et al..Defining a new diagnostic assessment parameter for wound care: elevated protease activity, an indicator of nonhealing, for targeted protease-modulating treatment. Wound Repair Regen, 2016; 24:589–595.
KessenbrockK, FrohlichL, SixtM, et al.Proteinase 3 and neutrophil elastase enhance inflammation in mice by inactivating antiinflammatory progranulin. J Clin Invest, 2008; 118:2438–2447.
23.
ChenSM, WardSI, OlutoyeOO, DiegelmannRF, Kelman CohenI. Ability of chronic wound fluids to degrade peptide growth factors is associated with increased levels of elastase activity and diminished levels of proteinase inhibitors. Wound Repair Regen, 1997; 5:23–32.
24.
SeniorRM, HuangJS, GriffinGL, DeuelTF. Dissociation of the chemotactic and mitogenic activities of platelet-derived growth factor by human neutrophil elastase. J Cell Biol, 1985; 100:351–356.
25.
KoriaP, YagiH, KitagawaY, et al..Self-assembling elastin-like peptides growth factor chimeric nanoparticles for the treatment of chronic wounds. Proc Natl Acad Sci U S A, 2011; 108:1034–1039.
26.
UrryDW.Physical chemistry of biological free energy transduction as demonstrated by elastic protein-based polymers. J Phys Chem B, 1997; 101:11007–11028.
27.
MeyerDE, ChilkotiA. Purification of recombinant proteins by fusion with thermally-responsive polypeptides. Nat Biotechnol, 1999; 17:1112–1115.
28.
LeonardA, KoriaP. Growth factor functionalized biomaterial for drug delivery and tissue regeneration. J Bioact Compat Polym, 2017; 32:568–581.
29.
McCarthyB, YuanY, KoriaP. Elastin-like-polypeptide based fusion proteins for osteogenic factor delivery in bone healing. Biotechnol Prog, 2016; 32:1029–1037.
30.
JohnsonT, KoriaP. Expression and purification of neurotrophin-elastin-like peptide fusion proteins for neural regeneration. BioDrugs, 2016; 30:117–127.
31.
KellenbergerC, BoudierC, BermudezI, BiethJG, LuuB, HietterH. Serine protease inhibition by insect peptides containing a cysteine knot and a triple-stranded beta-sheet. J Biol Chem, 1995; 270:25514–25519.
32.
DinhT, BraunagelS, RosenblumBI. Growth factors in wound healing: the present and the future?. Clin Podiatr Med Surg, 2015; 32:109–119.
33.
CastronuovoJJJr., GhobrialI, GiustiAM, RudolphS, SmiellJM.Effects of chronic wound fluid on the structure and biological activity of becaplermin (rhPDGF-BB) and becaplermin gel. Am J Surg, 1998; 176:61S–67S.
34.
WiemanTJ.Clinical efficacy of becaplermin (rhPDGF-BB) gel. Becaplermin Gel Studies Group. Am J Surg, 1998; 176:74S–79S.
35.
GilliganAM, WaycasterCR, MilneCT. Cost effectiveness of becaplermin gel on wound closure for the treatment of pressure injuries. Wounds, 2018; 30:197–204.
36.
LauerG, SollbergS, ColeM, KriegT, EmingSA. Generation of a novel proteolysis resistant vascular endothelial growth factor165 variant by a site-directed mutation at the plasmin sensitive cleavage site. FEBS Lett, 2002; 531:309–313.
37.
MineurP, ColigeAC, DeroanneCF, et al.Newly identified biologically active and proteolysis-resistant VEGF-A isoform VEGF111 is induced by genotoxic agents. J Cell Biol, 2007; 179:1261–1273.
38.
MurrayMJ. Protease resistant pdgf and methods of use. Google Patents, 1992.
39.
YuanY, KoriaP. Proliferative activity of elastin-like-peptides depends on charge and phase transition. J Biomed Mater Res A, 2015; 104:697–706.
